Supplementary Tables S1-S10 from <i>ACTA2</i> Expression Predicts Survival and Is Associated with Response to Immune Checkpoint Inhibitors in Gastric Cancer

Supplementary Tables S1-S10 from <i>ACTA2</i> Expression Predicts Survival and Is Associated with Response to Immune Checkpoint Inhibitors in Gastric Cancer

<p>Supplementary Table 1. Univariable associations of the multivariable Cox proportional hazards model in the Yonsei cohort.Supplementary Table 2. Clinical characteristics of patients in the pooled validation cohort.Supplementary Table 3. Univariable associations of the multivariable Cox propo...

Saved in:

書目詳細資料
主要作者:	Sunho Park (15053897) (author)
其他作者:	John D. Karalis (12209200) (author), Changjin Hong (15053900) (author), Jean R. Clemenceau (14941146) (author), Matthew R. Porembka (14941158) (author), In-Ho Kim (15053903) (author), Sung Hak Lee (15053906) (author), Sam C. Wang (12209239) (author), Jae-Ho Cheong (13946606) (author), Tae Hyun Hwang (15053909) (author)
出版:	2025
主題:	Cancer Cancer Detection and Diagnosis Immuno-oncology Methods and Technology Biomarkers Genetic biomarkers Prognostic biomarkers Computational Methods Gene expression profiling Gastrointestinal Cancers Stomach cancer Immunotherapy Checkpoint blockade Single Cell Technologies
標簽:	添加標簽沒有標簽, 成為第一個標記此記錄!

相似書籍

Supplementary Table S1 from Immunostimulatory Cancer-Associated Fibroblast Subpopulations Can Predict Immunotherapy Response in Head and Neck Cancer
由: Aleksandar Obradovic (7549517)
出版: (2025)

Supplementary Table S2 from Immunostimulatory Cancer-Associated Fibroblast Subpopulations Can Predict Immunotherapy Response in Head and Neck Cancer
由: Aleksandar Obradovic (7549517)
出版: (2025)

Supplementary Figure S1 from Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non–Small Cell Lung Cancer: The Piedmont Study
由: Joel R. Eisner (15132120)
出版: (2025)

Supplementary Figure S2 from Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non–Small Cell Lung Cancer: The Piedmont Study
由: Joel R. Eisner (15132120)
出版: (2025)

Supplementary Table S2 from Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non–Small Cell Lung Cancer: The Piedmont Study
由: Joel R. Eisner (15132120)
出版: (2025)

Supplementary Data S1 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
由: Steven B. Maron (15044607)
出版: (2025)

Supplementary Figure S10 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
由: Rohit Thummalapalli (17314483)
出版: (2025)

Figure 1 from Predicting Molecular Subtype and Survival of Rhabdomyosarcoma Patients Using Deep Learning of H&E Images: A Report from the Children's Oncology Group
由: David Milewski (15050643)
出版: (2025)

Figure 2 from Predicting Molecular Subtype and Survival of Rhabdomyosarcoma Patients Using Deep Learning of H&E Images: A Report from the Children's Oncology Group
由: David Milewski (15050643)
出版: (2025)

Figure 3 from Predicting Molecular Subtype and Survival of Rhabdomyosarcoma Patients Using Deep Learning of H&E Images: A Report from the Children's Oncology Group
由: David Milewski (15050643)
出版: (2025)

Figure 4 from Predicting Molecular Subtype and Survival of Rhabdomyosarcoma Patients Using Deep Learning of H&E Images: A Report from the Children's Oncology Group
由: David Milewski (15050643)
出版: (2025)

Figure 5 from Predicting Molecular Subtype and Survival of Rhabdomyosarcoma Patients Using Deep Learning of H&E Images: A Report from the Children's Oncology Group
由: David Milewski (15050643)
出版: (2025)

Figure 6 from Predicting Molecular Subtype and Survival of Rhabdomyosarcoma Patients Using Deep Learning of H&E Images: A Report from the Children's Oncology Group
由: David Milewski (15050643)
出版: (2025)

Supplementary Data 1 from Monitoring Sarcoma Response to Immune Checkpoint Inhibition and Local Cryotherapy with Circulating Tumor DNA Analysis
由: Nam Q. Bui (14958210)
出版: (2025)

Supplementary Appendix S1 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy
由: Bouchra Tawk (15389486)
出版: (2025)

Supplementary Table S1-S3 from Predicting Molecular Subtype and Survival of Rhabdomyosarcoma Patients Using Deep Learning of H&E Images: A Report from the Children's Oncology Group
由: David Milewski (15050643)
出版: (2025)

Supplementary Figure S1 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
由: Kala Visvanathan (14952973)
出版: (2025)

Supplementary Figure S2 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
由: Kala Visvanathan (14952973)
出版: (2025)

Supplementary Figure S3 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
由: Kala Visvanathan (14952973)
出版: (2025)

Supplementary Figure S4 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
由: Kala Visvanathan (14952973)
出版: (2025)

Supplementary Figure S5 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
由: Kala Visvanathan (14952973)
出版: (2025)

Supplementary Figure S10 from Elucidating the Genetic Landscape of Oral Leukoplakia to Predict Malignant Transformation
由: Leon J. Wils (15055780)
出版: (2025)

Supplementary Data 1 from The Mutational Landscape of Cancer's Vulnerability to Ionizing Radiation
由: Priyanka Gopal (15050862)
出版: (2025)

Supplementary Data 2 from The Mutational Landscape of Cancer's Vulnerability to Ionizing Radiation
由: Priyanka Gopal (15050862)
出版: (2025)

Supplementary Data 3 from The Mutational Landscape of Cancer's Vulnerability to Ionizing Radiation
由: Priyanka Gopal (15050862)
出版: (2025)

Supplementary Data 4 from The Mutational Landscape of Cancer's Vulnerability to Ionizing Radiation
由: Priyanka Gopal (15050862)
出版: (2025)

Supplementary Data 5 from The Mutational Landscape of Cancer's Vulnerability to Ionizing Radiation
由: Priyanka Gopal (15050862)
出版: (2025)

Supplementary Data 6 from The Mutational Landscape of Cancer's Vulnerability to Ionizing Radiation
由: Priyanka Gopal (15050862)
出版: (2025)

Figure S1 from <i>De Novo</i> and Histologically Transformed Small-Cell Lung Cancer Is Sensitive to Lurbinectedin Treatment Through the Modulation of EMT and NOTCH Signaling Pathways
由: Subhamoy Chakraborty (16648124)
出版: (2025)

Figure S2 from <i>De Novo</i> and Histologically Transformed Small-Cell Lung Cancer Is Sensitive to Lurbinectedin Treatment Through the Modulation of EMT and NOTCH Signaling Pathways
由: Subhamoy Chakraborty (16648124)
出版: (2025)

Figure S3 from <i>De Novo</i> and Histologically Transformed Small-Cell Lung Cancer Is Sensitive to Lurbinectedin Treatment Through the Modulation of EMT and NOTCH Signaling Pathways
由: Subhamoy Chakraborty (16648124)
出版: (2025)

Table S2 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
由: Joseph Toker (15399882)
出版: (2025)

Table S3 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
由: Joseph Toker (15399882)
出版: (2025)

Table S4 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
由: Joseph Toker (15399882)
出版: (2025)

Table S5 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
由: Joseph Toker (15399882)
出版: (2025)

Table S6 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
由: Joseph Toker (15399882)
出版: (2025)

Table S7 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
由: Joseph Toker (15399882)
出版: (2025)

Table S8 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
由: Joseph Toker (15399882)
出版: (2025)

Supplementary Tables 1-3 from <i>De Novo</i> and Histologically Transformed Small-Cell Lung Cancer Is Sensitive to Lurbinectedin Treatment Through the Modulation of EMT and NOTCH Signaling Pathways
由: Subhamoy Chakraborty (16648124)
出版: (2025)

Supplementary Table S1 from Development of Combination Strategies for Focal Adhesion Kinase Inhibition in Diffuse Gastric Cancer
由: Ke Peng (15048177)
出版: (2025)

Cannot write session to /tmp/vufind_sessions/sess_tgnlmompbfv45sj1c9sl8turck